Molecular profiling in colorectal cancer: current state of play and future directions

• Center MM , JemalA, WardE. International trends in colorectal cancer incidence rates. Cancer Epidemiol. Biomarkers Prev.18(6), 1688–1694 (2009).
   PubMed Web of Science ®Google Scholar
• Center MM , JemalA, SmithRA, WardE. Worldwide variations in colorectal cancer. CA Cancer J. Clin.59(6), 366–378 (2009).
   PubMed Web of Science ®Google Scholar
• Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• WHO Classification of Tumours of the Digestive System. Bosman FT, Carnerio F, Hruban RH, Theise ND (Eds). International Agency for Research on Cancer Press, Lyon, France (2010).
   Google Scholar
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds). International Agency for Research on Cancer Press, Lyon, France (2004).
   Google Scholar
• Grady WM , CarethersJM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology135(4), 1079–1099 (2008).
   PubMed Web of Science ®Google Scholar
• Jass JR . Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology50(1), 113–130 (2007).
   PubMed Web of Science ®Google Scholar
• Walther A , HoulstonR, TomlinsonI. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut57(7), 941–950 (2008).
   PubMed Web of Science ®Google Scholar
• Hughes LA , Khalid-De Bakker CA, Smits KMet al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim. Biophys. Acta1825(1), 77–85 (2012).
   PubMed Web of Science ®Google Scholar
• Patai AV , MolnarB, KalmarA, SchollerA, TothK, TulassayZ. Role of DNA methylation in colorectal carcinogenesis. Dig. Dis.30(3), 310–315 (2012).
   PubMed Web of Science ®Google Scholar
• Cunningham D , AtkinW, LenzHJet al. Colorectal cancer. Lancet 375(9719), 1030–1047 (2010).
   PubMed Web of Science ®Google Scholar
• Fearon ER . Molecular genetics of colorectal cancer. Annu. Rev. Pathol.6, 479–507 (2011).
   PubMed Web of Science ®Google Scholar
• Simons CC , HughesLA, SmitsKMet al. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann. Oncol. 24(8), 2048–2056 (2013).
   PubMed Web of Science ®Google Scholar
• Vogelstein B , FearonER, HamiltonSRet al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319(9), 525–532 (1988).
   PubMed Web of Science ®Google Scholar
• Fensterer H , RadlwimmerB, StraterJet al. Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks. BMC Cancer 7, 58 (2007).
   PubMed Web of Science ®Google Scholar
• Watanabe T , Kobunai T, Yamamoto Yet al. Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J. Clin. Oncol.30(18), 2256–2264 (2012).
   PubMed Web of Science ®Google Scholar
• Davies JM , GoldbergRM. Treatment of metastatic colorectal cancer. Semin. Oncol.38(4), 552–560 (2011).
   PubMed Web of Science ®Google Scholar
• Hewish M , LordCJ, MartinSA, CunninghamD, AshworthA. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat. Rev. Clin. Oncol.7(4), 197–208 (2010).
   PubMed Web of Science ®Google Scholar
• Poulogiannis G , FraylingIM, ArendsMJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology56(2), 167–179 (2010).
   PubMed Web of Science ®Google Scholar
• Boland CR , GoelA. Microsatellite instability in colorectal cancer. Gastroenterology138(6), 2073.e3–2087.e3 (2010).
   PubMed Web of Science ®Google Scholar
• Greenson JK , BonnerJD, Ben-YzhakOet al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am. J. Surg. Pathol. 27(5), 563–570 (2003).
   PubMed Web of Science ®Google Scholar
• Ribic CM , SargentDJ, MooreMJet al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247–257 (2003).
   PubMed Web of Science ®Google Scholar
• Deng G , BellI, CrawleySet al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res.10(1 Pt 1), 191–195 (2004).
   PubMed Web of Science ®Google Scholar
• Domingo E , LaihoP, OllikainenMet al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet. 41(9), 664–668 (2004).
   PubMed Web of Science ®Google Scholar
• Bedeir A , KrasinskasAM. Molecular diagnostics of colorectal cancer. Arch. Pathol. Lab. Med.135(5), 578–587 (2011).
   PubMed Web of Science ®Google Scholar
• Boland CR , ThibodeauSN, HamiltonSRet al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58(22), 5248–5257 (1998).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bigas MA , BolandCR, HamiltonSRet al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J. Natl Cancer Inst. 89(23), 1758–1762 (1997).
   PubMedGoogle Scholar
• Baudhuin LM , BurgartLJ, LeontovichO, ThibodeauSN. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam. Cancer4(3), 255–265 (2005).
   PubMed Web of Science ®Google Scholar
• Popat S , HubnerR, HoulstonRS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol.23(3), 609–618 (2005).
   PubMed Web of Science ®Google Scholar
• Vilar E , GruberSB. Microsatellite instability in colorectal cancer – the stable evidence. Nat. Rev. Clin. Oncol.7(3), 153–162 (2010).
   PubMed Web of Science ®Google Scholar
• Jones PA , BaylinSB. The epigenomics of cancer. Cell128(4), 683–692 (2007).
   PubMed Web of Science ®Google Scholar
• Bird A . DNA methylation patterns and epigenetic memory. Genes Dev.16(1), 6–21 (2002).
   PubMed Web of Science ®Google Scholar
• Jones PA . Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet.13(7), 484–492 (2012).
   PubMed Web of Science ®Google Scholar
• Chan TL , YuenST, KongCKet al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet. 38(10), 1178–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Hitchins M , WilliamsR, CheongKet al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology129(5), 1392–1399 (2005).
   PubMed Web of Science ®Google Scholar
• Horsthemke B . Heritable germline epimutations in humans. Nat. Genet.39(5), 573–574; author reply 575–576 (2007).
   PubMed Web of Science ®Google Scholar
• Suter CM , MartinDI, WardRL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet.36(5), 497–501 (2004).
   PubMed Web of Science ®Google Scholar
• Issa JP , OttavianoYL, CelanoP, HamiltonSR, DavidsonNE, BaylinSB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet.7(4), 536–540 (1994).
   PubMed Web of Science ®Google Scholar
• Park SJ , RashidA, LeeJH, KimSG, HamiltonSR, WuTT. Frequent CpG island methylation in serrated adenomas of the colorectum. Am. J. Pathol.162(3), 815–822 (2003).
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ , SiegmundKD, CampanMet al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38(7), 787–793 (2006).
   PubMed Web of Science ®Google Scholar
• Ogino S , KawasakiT, KirknerGJ, KraftP, LodaM, FuchsCS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J. Mol. Diagn.9(3), 305–314 (2007).
   PubMed Web of Science ®Google Scholar
• Shen L , ToyotaM, KondoYet al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104(47), 18654–18659 (2007).
   PubMed Web of Science ®Google Scholar
• Ogino S , KawasakiT, NoshoKet al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int. J. Cancer122(12), 2767–2773 (2008).
   PubMed Web of Science ®Google Scholar
• Nosho K , IraharaN, ShimaKet al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 3(11), e3698 (2008).
   PubMed Web of Science ®Google Scholar
• Silver A , SenguptaN, PropperDet al. A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers. Int. J. Cancer 130(5), 1082–1092 (2012).
   PubMed Web of Science ®Google Scholar
• Samowitz WS , AlbertsenH, HerrickJet al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129(3), 837–845 (2005).
   PubMed Web of Science ®Google Scholar
• Samowitz WS , AlbertsenH, SweeneyCet al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J. Natl Cancer Inst. 98(23), 1731–1738 (2006).
   PubMed Web of Science ®Google Scholar
• Ogino S , NoshoK, KirknerGJet al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58(1), 90–96 (2009).
   PubMed Web of Science ®Google Scholar
• Shen L , CatalanoPJ, BensonAB 3rd, O‘Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res.13(20), 6093–6098 (2007).
   PubMed Web of Science ®Google Scholar
• Bibeau F , Boissiere-MichotF, SabourinJCet al. Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch. 449(3), 281–287 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein NS , ArminM. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer92(5), 1331–1346 (2001).
   PubMed Web of Science ®Google Scholar
• Amado RG , WolfM, PeetersMet al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Karapetis CS , Khambata-FordS, JonkerDJet al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KohneCH, LangIet al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• De Roock W , ClaesB, BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8), 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Troiani T , ZappavignaS, MartinelliEet al. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin. Biol. Ther. 13(2), 241–255 (2013).
   PubMed Web of Science ®Google Scholar
• Wiesweg M , TingS, ReisHet al. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. Eur. J. Cancer 49(15), 3076–3082 (2013).
   PubMed Web of Science ®Google Scholar
• Bertotti A , MigliardiG, GalimiFet al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1(6), 508–523 (2011).
   PubMed Web of Science ®Google Scholar
• Ooi A , TakehanaT, LiXet al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod. Pathol. 17(8), 895–904 (2004).
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular characterization of human colon and rectal cancer. Nature487(7407), 330–337 (2012).
   PubMed Web of Science ®Google Scholar
• Migliore L , MigheliF, SpisniR, CoppedeF. Genetics, cytogenetics, and epigenetics of colorectal cancer. J. Biomed. Biotechnol.2011, 792362 (2011).
   PubMedGoogle Scholar
• Lurje G , ZhangW, LenzHJ. Molecular prognostic markers in locally advanced colon cancer. Clin. Colorectal Cancer6(10), 683–690 (2007).
   PubMed Web of Science ®Google Scholar
• Thibodeau SN , BrenG, SchaidD. Microsatellite instability in cancer of the proximal colon. Science260(5109), 816–819 (1993).
   PubMed Web of Science ®Google Scholar
• Jacobs B , De Roock W, Piessevaux Het al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol.27(30), 5068–5074 (2009).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S , GarrettCR, MeropolNJet al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230–3237 (2007).
   PubMed Web of Science ®Google Scholar
• Ramaswamy S , TamayoP, RifkinRet al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA 98(26), 15149–15154 (2001).
   PubMed Web of Science ®Google Scholar
• Su AI , WelshJB, SapinosoLMet al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 61(20), 7388–7393 (2001).
   PubMed Web of Science ®Google Scholar
• Lascorz J , ChenB, HemminkiK, ForstiA. Consensus pathways implicated in prognosis of colorectal cancer identified through systematic enrichment analysis of gene expression profiling studies. PLoS ONE6(4), e18867 (2011).
   PubMed Web of Science ®Google Scholar
• Lepesheva GI , WatermanMR. Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim. Biophys. Acta1770(3), 467–477 (2007).
   PubMed Web of Science ®Google Scholar
• Tsunedomi R , IizukaN, HamamotoYet al. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int. J. Oncol. 27(3), 661–667 (2005).
   PubMed Web of Science ®Google Scholar
• Gimba ER , TilliTM. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett.331(1), 11–17 (2013).
   PubMed Web of Science ®Google Scholar
• Weber GF , AshkarS, GlimcherMJ, CantorH. Receptor–ligand interaction between CD44 and osteopontin (Eta-1). Science271(5248), 509–512 (1996).
   PubMed Web of Science ®Google Scholar
• Chambers AF , WilsonSM, KerkvlietN, O‘MalleyFP, HarrisJF, CassonAG. Osteopontin expression in lung cancer. Lung Cancer15(3), 311–323 (1996).
   PubMed Web of Science ®Google Scholar
• Hotte SJ , WinquistEW, StittL, WilsonSM, ChambersAF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer95(3), 506–512 (2002).
   PubMed Web of Science ®Google Scholar
• Tuck AB , ChambersAF. The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia6(4), 419–429 (2001).
   PubMed Web of Science ®Google Scholar
• Roepman P , SchlickerA, TaberneroJet al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 134(3), 552–562 (2013).
   PubMed Web of Science ®Google Scholar
• Spruessel A , SteimannG, JungMet al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 36(6), 1030–1037 (2004).
   PubMed Web of Science ®Google Scholar
• Reya T , MorrisonSJ, ClarkeMF, WeissmanIL. Stem cells, cancer, and cancer stem cells. Nature414(6859), 105–111 (2001).
   PubMed Web of Science ®Google Scholar
• Horst D , ScheelSK, LiebmannSet al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J. Pathol. 219(4), 427–434 (2009).
   PubMed Web of Science ®Google Scholar
• Vermeulen L , TodaroM, De Sousa Mello Fet al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl Acad. Sci. USA105(36), 13427–13432 (2008).
   PubMed Web of Science ®Google Scholar
• Chen S , SongX, ChenZet al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS ONE 8(2), e56380 (2013).
   PubMed Web of Science ®Google Scholar
• Kemper K , VerslootM, CameronKet al. Mutations in the Ras–Raf axis underlie the prognostic value of CD133 in colorectal cancer. Clin. Cancer Res. 18(11), 3132–3141 (2012).
   PubMed Web of Science ®Google Scholar
• Ide T , KitajimaY, OhtakaK, MitsunoM, NakafusaY, MiyazakiK. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Oncol. Rep.19(6), 1571–1576 (2008).
   PubMed Web of Science ®Google Scholar
• Jover R , NguyenTP, Perez-CarbonellLet al. 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140(4), 1174–1181 (2011).
   PubMed Web of Science ®Google Scholar
• Van Rijnsoever M , ElsalehH, JosephD, MccaulK, IacopettaB. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res.9(8), 2898–2903 (2003).
   PubMed Web of Science ®Google Scholar
• De Maat MF , Van De Velde CJ, Benard Aet al. Identification of a quantitative MINT locus methylation profile predicting local regional recurrence of rectal cancer. Clin. Cancer Res.16(10), 2811–2818 (2010).
   PubMed Web of Science ®Google Scholar
• De Maat MF , Van De Velde CJ, Van Der Werff MPet al. Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. J. Clin. Oncol.26(14), 2327–2335 (2008).
   PubMed Web of Science ®Google Scholar
• Kuremsky JG , TepperJE, McleodHL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.74(3), 673–688 (2009).
   PubMed Web of Science ®Google Scholar
• Molinari C , Casadio V, Foca Fet al. Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy? J. Cell Physiol.228(12), 2343–2349 (2013).
   PubMed Web of Science ®Google Scholar
• Kim MS , LeeJ, SidranskyD. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev.29(1), 181–206 (2010).
   PubMed Web of Science ®Google Scholar
• Ahn JB , ChungWB, MaedaOet al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117(9), 1847–1854 (2011).
   PubMed Web of Science ®Google Scholar
• Antelo M , BalaguerF, ShiaJet al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS ONE 7(9), e45357 (2012).
   PubMed Web of Science ®Google Scholar
• Ogino S , NoshoK, KirknerGJet al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl Cancer Inst. 100(23), 1734–1738 (2008).
   PubMedGoogle Scholar
• Sakamoto N , TeraiT, AjiokaYet al. Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors. Oncogene 23(55), 8900–8907 (2004).
   PubMed Web of Science ®Google Scholar
• Ramirez N , BandresE, NavarroAet al. Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions. Eur. J. Cancer 44(17), 2689–2695 (2008).
   PubMed Web of Science ®Google Scholar
• Lee Y , AhnC, HanJet al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415–419 (2003).
   PubMed Web of Science ®Google Scholar
• Calin GA , SevignaniC, DumitruCDet al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101(9), 2999–3004 (2004).
   PubMed Web of Science ®Google Scholar
• Pin AL , HouleF, HuotJ. Recent advances in colorectal cancer research: the microenvironment impact. Cancer Microenviron.4(2), 127–131 (2011).
   PubMedGoogle Scholar
• Sun G , YanJ, NoltnerKet al. SNPs in human miRNA genes affect biogenesis and function. RNA 15(9), 1640–1651 (2009).
   PubMed Web of Science ®Google Scholar
• Hrasovec S , GlavacD. MicroRNAs as novel biomarkers in colorectal cancer. Front. Genet.3, 180 (2012).
   PubMedGoogle Scholar
• Mazeh H , MizrahiI, IlyayevNet al. The diagnostic and prognostic role of microrna in colorectal cancer – a comprehensive review. J. Cancer 4(3), 281–295 (2013).
   PubMed Web of Science ®Google Scholar
• Lanza G , FerracinM, GafàRet al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer 6, 54 (2007).
   PubMed Web of Science ®Google Scholar
• Balaguer F , MoreiraL, LozanoJJet al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin. Cancer Res. 17(19), 6239–6249 (2011).
   PubMed Web of Science ®Google Scholar
• Chang K h, Miller N, Kheirelseid EH. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int. J. Colorectal Dis.26(11), 1415–1422 (2011).
   PubMed Web of Science ®Google Scholar
• Nishida N , YamashitaS, MimoriKet al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann. Surg. Oncol. 19(9), 3065–3071 (2012).
   PubMed Web of Science ®Google Scholar
• Iorio MV , FerracinM, LiuCGet al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065–7070 (2005).
   PubMed Web of Science ®Google Scholar
• Yanaihara N , CaplenN, BowmanEet al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189–198 (2006).
   PubMed Web of Science ®Google Scholar
• Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res.67(13), 6130–6135 (2007).
   PubMed Web of Science ®Google Scholar
• Park SY , LeeJH, HaM, NamJW, KimVN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat. Struct. Mol. Biol.16(1), 23–29 (2009).
   PubMed Web of Science ®Google Scholar
• Weissmann-Brenner A , KushnirM, Lithwick Yanai Get al. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Int. J. Oncol.40(6), 2097–2103 (2012).
   PubMed Web of Science ®Google Scholar
• Yang IP , TsaiHL, HuangCWet al. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One 8(6), e66842 (2013).
   PubMed Web of Science ®Google Scholar
• Kuo TY , HsiE, YangIPet al. Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS One 7(2), e31587 (2012).
   PubMed Web of Science ®Google Scholar
• Imperiale TF , RansohoffDF, ItzkowitzSH, TurnbullBA, RossME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med.351(26), 2704–2714 (2004).
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr , Williams RT, Wu Jet al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature486(7404), 537–540 (2012).
   PubMed Web of Science ®Google Scholar
• Lecomte T , BergerA, ZinzindohoueFet al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 100(5), 542–548 (2002).
   PubMed Web of Science ®Google Scholar
• Heitzer E , AuerM, HoffmannEMet al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int. J. Cancer 133(2), 346–356 (2013).
   PubMed Web of Science ®Google Scholar
• Devos T , TetznerR, ModelFet al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55(7), 1337–1346 (2009).
   PubMed Web of Science ®Google Scholar
• Grutzmann R , MolnarB, PilarskyCet al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 3(11), e3759 (2008).
   PubMed Web of Science ®Google Scholar
• Liu Y , ThamCK, OngSYet al. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study. Biomarkers 18(5), 399–405 (2013).
   PubMed Web of Science ®Google Scholar
• Toth K , GalambO, SpisakSet al. The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer. Pathol. Oncol. Res. 17(3), 503–509 (2011).
   PubMed Web of Science ®Google Scholar
• Toth K , SiposF, KalmarAet al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE 7(9), e46000 (2012).
   PubMed Web of Science ®Google Scholar
• Warren JD , Xiong W, Bunker AMet al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med.9, 133 (2011).
   PubMed Web of Science ®Google Scholar
• Lofton-Day C , ModelF, DevosTet al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54(2), 414–423 (2008).
   PubMed Web of Science ®Google Scholar
• Nagasaka T , TanakaN, CullingsHMet al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl Cancer Inst. 101(18), 1244–1258 (2009).
   PubMedGoogle Scholar
• Bujanda L , SarasquetaC, CosmeAet al. Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer. PLoS ONE 8(1), e51810 (2013).
   PubMed Web of Science ®Google Scholar
• Davidson LA , LuptonJR, MiskovskyE, FieldsAP, ChapkinRS. Quantification of human intestinal gene expression profiles using exfoliated colonocytes: a pilot study. Biomarkers8(1), 51–61 (2003).
   PubMed Web of Science ®Google Scholar
• Kanaoka S , YoshidaK, MiuraN, SugimuraH, KajimuraM. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology127(2), 422–427 (2004).
   PubMed Web of Science ®Google Scholar

Websites

• GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC CancerBase No 10. http://globocan.iarc.fr/Default.aspx
   Google Scholar
• Cosmic Release v67. http://cancer.sanger.ac.uk/cancergenome/projects/cosmic
   Google Scholar